Skip to content

Bio-Rad Laboratories

US · BIO #1479 by market cap Listed 1970
358.90 -8.60 -2.34%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 12 in the most recent period (2026/Q3).
  • Total institutional ownership rose 0.1 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
88.70% +0.12pp
Institutions
490 +12
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund60.27%
Private Company16.16%
Public Company5.40%
Hedge Fund5.30%
Individual/Insider4.75%
Government Pension Fund0.86%
Sovereign Wealth Fund0.42%
Insurance Company0.16%
Other6.62%

Top holders as of 2026-09-01

Blue Raven Partners, L.P. 15.10% · 4.06M sh
First Eagle Investment Management, LLC 9.13% · 2.46M sh
BlackRock 6.47% · 1.74M sh
Norman Schwartz 4.56% · 1.23M sh
Capital Research 3.55% · 955.54K sh
Dimensional Fund Advisors 3.29% · 885.98K sh
Vanguard Capital Management, LLC 3.08% · 827.20K sh
Ariel Investments, LLC 3.04% · 816.75K sh
Vanguard Portfolio Management, LLC 3.02% · 811.56K sh
UBS Asset Management 2.42% · 650.63K sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 29 buys · 21 sells

NameRoleStake
Norman Schwartz Chairperson & CEO 4.56%
Colleen Corey Former Executive Vice President of Global Human Resources 0.07%
Michael Crowley Executive Vice President of Global Commercial Operations 0.03%
Allison Schwartz Director 0.02%
Sedat Evran Executive Vice President of Global Supply Chain 0.02%
Roop Lakkaraju Chief Financial Officer 0.02%
Jonathan DiVincenzo President 0.01%
James Barry Executive VP & President of Life Science Group 0.01%
Eva Engelhardt Executive VP & President of the Clinical Diagnostics Group 0.01%
Rajat Mehta Executive Vice President of Global Commercial Operations 0.00%
Courtney Enloe General Counsel 0.01%
Gregory Hinckley Lead Independent Director 0.00%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-09 Courtney Enloe General Counsel Open Market Disposition -902 $386.17
2026-11-08 Jonathan DiVincenzo President Open Market Disposition -919 $390.47
2026-11-08 James Barry Executive VP & President of Life Science Group Open Market Disposition -1,400 $385.63
2026-10-23 Jonathan DiVincenzo President Derivative Exercise and Sale -951 $369.95
2026-10-23 Jonathan DiVincenzo President Derivative Exercise and Retained +918 --
2026-10-19 Sedat Evran Executive Vice President of Global Supply Chain Derivative Exercise and Sale -487 $354.50
2026-10-19 Sedat Evran Executive Vice President of Global Supply Chain Derivative Exercise and Retained +557 --
2026-09-05 Norman Schwartz Chairperson & CEO Derivative Exercise and Sale -4,730 $386.11
2026-09-05 Norman Schwartz Chairperson & CEO Derivative Exercise and Retained +2,834 --
2026-09-05 Roop Lakkaraju Chief Financial Officer Derivative Exercise and Sale -1,341 $386.11
2026-09-05 Roop Lakkaraju Chief Financial Officer Derivative Exercise and Retained +1,565 --
2026-09-05 Eva Engelhardt Executive VP & President of the Clinical Diagnostics Group Derivative Exercise and Sale -854 $386.11
2026-09-05 Eva Engelhardt Executive VP & President of the Clinical Diagnostics Group Derivative Exercise and Retained +1,325 --
2026-09-05 Allison Schwartz Director Derivative Exercise and Sale -116 $386.11
2026-09-05 Allison Schwartz Director Derivative Exercise and Retained +204 --
2026-09-05 James Barry Executive VP & President of Life Science Group Derivative Exercise and Sale -839 $386.11
2026-09-05 James Barry Executive VP & President of Life Science Group Derivative Exercise and Retained +1,244 --
2026-09-05 Sedat Evran Executive Vice President of Global Supply Chain Derivative Exercise and Sale -606 $386.11
2026-09-05 Sedat Evran Executive Vice President of Global Supply Chain Derivative Exercise and Retained +1,285 --
2026-09-05 Courtney Enloe General Counsel Derivative Exercise and Sale -551 $386.11

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Bio-Rad Laboratories discussion 0 comments

Add a comment